Skip to main content
PMC home page
Applied Microbiology logoLink to Applied Microbiology
. 1970 Jun;19(6):955–959. doi: 10.1128/am.19.6.955-959.1970

Amphotericin B Serum Concentrations During Therapy 1

Branch T Fields Jr 1,2, Joseph H Bates 1, Robert S Abernathy 1
PMCID: PMC376832  PMID: 5456013

Abstract

Therapeutic outcome of patients being treated for systemic mycoses with amphotericin B is possibly related to the serum concentrations of this drug that are produced in these patients. Because current data are conflicting, the magnitude of these concentrations was restudied by using a bioassay which gave precise and accurate results. The highest of 155 serum concentrations was 2.01 μg/ml. Mean concentrations were 1.21, 0.62, and 0.32 μg/ml, at 1, 18, and 42 hr, respectively, after intravenous infusion of amphotericin B. This drug was detected in serum 7 weeks after completion of treatment, but it could not be detected 13 weeks after treatment. Drug levels did not appreciably decrease in serum stored for 8 to 9 months at − 10 C. Unequal serum content in assay tubes and measurement of assay turbidity by visual inspection may explain previously reported amphotericin B levels of 3.0 to 12.5 μg/ml.

Full text

PDF
956

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BAUM G. L., ARTIS D. Fungistatic effects of cell free human serum. Am J Med Sci. 1961 Dec;242:761–770. doi: 10.1097/00000441-196112000-00015. [DOI] [PubMed] [Google Scholar]
  2. BLOUNT J. G. BACTERIAL ENDOCARDITIS. Am J Med. 1965 Jun;38:909–922. doi: 10.1016/0002-9343(65)90010-0. [DOI] [PubMed] [Google Scholar]
  3. Battock D. J., Grausz H., Bobrowsky M., Littman M. L. Alternate-day amphotericin B therapy in the treatment of rhinocerebral phycomycosis (mucormycosis). Ann Intern Med. 1968 Jan;68(1):122–137. doi: 10.7326/0003-4819-68-1-122. [DOI] [PubMed] [Google Scholar]
  4. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  5. Drutz D. J., Spickard A., Rogers D. E., Koenig M. G. Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. Am J Med. 1968 Sep;45(3):405–418. doi: 10.1016/0002-9343(68)90075-2. [DOI] [PubMed] [Google Scholar]
  6. GERACI J. E. The antibiotic therapy of bacterial endocarditis: therapeutic data on 172 patients seen from 1951 through 1957: additional observations on short-term therapy (two weeks) for penicillin-sensitivie streptococcal endocarditis. Med Clin North Am. 1958 Jul;42(4):1101–1140. doi: 10.1016/s0025-7125(16)34262-6. [DOI] [PubMed] [Google Scholar]
  7. GOTTLIEB D., CARTER H. E., SLONEKER J. H., AMMANN A. Protection of fungi against polyene antibiotics by sterols. Science. 1958 Aug 15;128(3320):361–361. doi: 10.1126/science.128.3320.361. [DOI] [PubMed] [Google Scholar]
  8. KRAMER J., KIRSHBAUM A. Cylinder plate assays for amphotericin B in dosage forms and body fluids. Antibiot Chemother. 1960 Mar;10:188–192. [PubMed] [Google Scholar]
  9. LAMPEN J. O., ARNOW P. M., SAFFERMAN R. S. Mechanism of protection by sterols against polyene antibiotics. J Bacteriol. 1960 Aug;80:200–206. doi: 10.1128/jb.80.2.200-206.1960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. LITTMAN M. L., HOROWITZ P. L., SWADEY J. G. Coccidioidomycosis and its treatment with amphotericin B. Am J Med. 1958 Apr;24(4):568–592. doi: 10.1016/0002-9343(58)90297-3. [DOI] [PubMed] [Google Scholar]
  11. LOURIA D. B. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther (New York) 1958 May;5(5):295–301. [PubMed] [Google Scholar]
  12. NEWCOMER V. D., STERNBERG T. H., WRIGHT E. T., REISNER R. M. Current status of amphotericin B in the treatment of the systemic fungus infections. J Chronic Dis. 1959 Apr;9(4):353–374. doi: 10.1016/0021-9681(59)90056-6. [DOI] [PubMed] [Google Scholar]
  13. Petersdorf R. G., Sherris J. C. Methods and significance of in vitro testing of bacterial sensitivity to drugs. Am J Med. 1965 Nov;39(5):766–779. doi: 10.1016/0002-9343(65)90096-3. [DOI] [PubMed] [Google Scholar]
  14. ROTH F. J., Jr, GOLDSTEIN M. I. Inhibition of growth of pathogenic yeasts by human serum. J Invest Dermatol. 1961 May;36:383–387. doi: 10.1038/jid.1961.59. [DOI] [PubMed] [Google Scholar]
  15. Rebell G. Effect of lipoproteins on hemolytic and antifungal activity of amphotericin B and other polyene antibiotics. Antimicrob Agents Chemother (Bethesda) 1966;6:411–418. doi: 10.1128/AAC.6.4.411. [DOI] [PubMed] [Google Scholar]
  16. SEABURY J. H., DASCOMB H. E. Experience with amphotericin B for the treatment of systemic mycoses. AMA Arch Intern Med. 1958 Dec;102(6):960–976. doi: 10.1001/archinte.1958.00260230106014. [DOI] [PubMed] [Google Scholar]
  17. SKEGGS L. T., Jr An automatic method for colorimetric analysis. Am J Clin Pathol. 1957 Sep;28(3):311–322. doi: 10.1093/ajcp/28.3_ts.311. [DOI] [PubMed] [Google Scholar]
  18. Shadomy S., McCay J. A., Schwartz S. I. Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol. 1969 Apr;17(4):497–503. doi: 10.1128/am.17.4.497-503.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. TUMULTY P. A. The management of bacterial endocarditis. Arch Intern Med. 1960 Jan;105:126–142. doi: 10.1001/archinte.1960.00270130142019. [DOI] [PubMed] [Google Scholar]
  20. VOGEL R. A., CRUTCHER J. C. Studies on the bioassay and excretion of amphotericin B in patients with systemic mycoses. Antibiotic Med Clin Ther (New York) 1958 Aug;5(8):501–506. [PubMed] [Google Scholar]
  21. WINN W. A. The use of amphotericin B in the treatment of coccidioidal disease. Am J Med. 1959 Oct;27:617–635. doi: 10.1016/0002-9343(59)90046-4. [DOI] [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES